

## Anti-TIGIT [1B4] VivopureX 25 mg Ab01258-2.0-VXX

This reformatted mouse antibody was made using the variable domain sequences of the original Mouse IgG1 format, for improved compatibility with existing reagents, assays and techniques.

**Isotype and Format:** Mouse IgG2a, Lambda

**Clone Number:** 1B4

**Alternative Name(s) of Target:** VSTM3; T cell Ig and ITIM domain; T cell immunoreceptor with Ig and ITIM domains; V-set and transmembrane domain-containing protein 3; WUCAM

**UniProt Accession Number of Target Protein:** P86176

**Published Application(s):** Blocking, ELISA, FC

**Published Species Reactivity:** Mouse

**Immunogen:** This antibody was raised by immunising TIGIT<sup>-/-</sup> mice with recombinant murine TIGIT tetramers.

**Specificity:** This antibody is specific for murine TIGIT.

**Application Notes:** The binding specificity of this antibody for TIGIT has been confirmed in ELISA analysis and by flow cytometry using P815 cells transfected with mouse TIGIT and activated mouse splenocytes (Dixon et al, 2018). This antibody also specifically stains activated primary wild-type T cells (Dixon et al, 2018). This antibody fully blocks CD155 binding to TIGIT, and acts as a TIGIT blocking antibody in vivo. Administration of this antibody increases experimental autoimmune encephalomyelitis (EAE) severity, and retards the growth of established MC38 colon carcinoma and GL261 glioblastoma (Dixon et al, 2018). This antibody synergises with anti-PD-1 blocking antibodies to achieve complete tumour regression in colon carcinoma models (Dixon et al, 2018). The original mouse IgG1 antibody does not deplete TIGIT-expressing CD4<sup>+</sup> or CD8<sup>+</sup> T cells in vivo, nor affect T cell proliferation in vitro (Dixon et al, 2018).

**Antibody First Published in:** Dixon et al. Functional Anti-TIGIT Antibodies Regulate Development of Autoimmunity and Antitumor Immunity J Immunol. 2018 Apr 15;200(8):3000-3007 [PMID:29500245](#)

**Note on publication:** Describes the original generation of this antibody, and the establishment of its TIGIT-blocking function.

## Product Form

**Size:** 25 mg VivopureX products are produced at high purity (>98%), low endotoxin (<0.5 EU/mg) and are formulated without preservatives. These antibodies are chimerized to have an Fc domain matching their target species to reduce immunogenicity and give you the optimal effector function for your experiment. As

a result VivopureX products are the ideal choice for in vivo research applications.

**Purification:** Protein A affinity purified

**Supplied In:** PBS only.

**Storage Recommendation:** All VivopureX products are formulated in PBS only without addition of preservatives. To ensure optimal storage and prevent microbial contamination, only open and dispense under sterile conditions.

**Concentration:**  $\geq 1$ mg (see vial label for exact conc)

Important note – This product is for research use only. It is not intended for use in therapeutic or diagnostic procedures for humans or animals.